His sudden resignation comes just three weeks after Gilead’s President and CEO John Milligan, PhD, announced he would depart at the end of the year and that Chairman John Martin would follow suit.
However, those aren’t the only notable departures since the beginning of 2018. The company’s Chief Scientific Officer Norbert Bischofberger, PhD, left in April, and Kevin Young, COO and executive vice president of communication, stepped down in February. In addition, James Meyers, the company’s head of commercial operations, retired in March.
Dr. Cheng, who is leaving to pursue another opportunity, will remain with Gilead until Sept. 7. He joined Gilead in 1999 and was promoted to CMO just five months ago.
More articles on pharmacy:
Pharmacy middlemen not to blame for high drug prices, CVS chief says
FDA generic drug approvals hit record high in July
Mylan’s Q2 revenue down 5%; US healthcare changes cited
